Multiple reports say Amgen’s multiple myeloma drug Tavneos (amivantamab-vmjw) has been linked to 20 deaths in Japan. The Japan Times reports that 20 people in Japan died after taking the treatment, citing a media report that raised concerns about the safety signals. However, the reporting also notes that it is unclear whether Tavneos is directly responsible for those deaths. The accounts describe that the linkage comes from reported outcomes following use of the drug, but they do not establish causation. Amgen’s Japanese partner is also described as discouraging further use, reflecting heightened caution while the matter is clarified. The sources do not provide additional details on the patients’ conditions, timing of death after dosing, or whether authorities or Amgen have completed a safety assessment. Overall, the available information focuses on reported temporal association and the resulting hesitancy, while emphasizing that the cause of the deaths has not been confirmed.